Abstract
Addition of the anti-CD38 monoclonal antibody isatuximab to lenalidomide–bortezomib–dexamethasone (RVd) could be a new standard of care for patients with newly diagnosed multiple myeloma, according to results from the GMMG HD7 trial, presented by Hartmut Goldschmidt (University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany). In this phase 3 trial, patients with newly diagnosed, transplantation-eligible multiple myeloma were randomly assigned to RVd (n=329) or RVd plus intravenous isatuximab (n=331) and assessed for minimal residual disease negativity after induction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
